Krystal Biotech (KRYS) Capital Expenditures (2016 - 2026)

Krystal Biotech has reported Capital Expenditures for 11 years, with the latest figure at $3.6 million in Q2 2026.

• Capital Expenditures for Q2 2026 came in at $3.6 million, up 87.24% year-over-year; the trailing twelve-month figure through Jun 2026 was $14.6 million (up 81.11% YoY), and the FY2025 annual result was $12.0 million, up 40.65% from the prior year.
• Capital Expenditures fell to $3.6 million in Q2 2026, from $7.1 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $17.2 million in Q1 2022 and troughed at -$867000.0 in Q2 2023.
• A 5-year average of $5.3 million and a median of $2.9 million in 2025 frame the typical range for Capital Expenditures.
• The widest annual swing landed in 2024, when Capital Expenditures slumped 362.86%; it then jumped 1600.0% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $5.2 million in 2022, then tumbled by 86.66% to $696000.0 in 2023, then plunged by 70.55% to $205000.0 in 2024, then surged by 943.41% to $2.1 million in 2025, then soared by 66.67% to $3.6 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $3.6 million in Q2 2026, $7.1 million in Q1 2026, and $2.1 million in Q4 2025.